Page last updated: 2024-08-23

pravastatin and Breast Cancer

pravastatin has been researched along with Breast Cancer in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (25.00)18.2507
2000's5 (62.50)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Auboire, L; Landy, S; Le Hello, C; Maïza, D; Perrot, JY1
Archer, MC; Duncan, RE; El-Sohemy, A1
Gebhardt, A; Niendorf, A1
Kuller, LH; Modan, B1
Verdery, R1
Lupattelli, G; Palumbo, B; Sinzinger, H1
Jick, H; Kaye, JA; Meier, CR; Walker, AM1
Braunwald, E; Byington, RP; Cobbe, SM; Davis, BR; Friedman, CP; Keech, A; Pfeffer, MA; Sacks, FM; Tonkin, A1

Reviews

2 review(s) available for pravastatin and Breast Cancer

ArticleYear
[A negative first-line work-up of Raynaud's phenomenon: And what if it were cancer?].
    Journal des maladies vasculaires, 2010, Volume: 35, Issue:1

    Topics: Adenocarcinoma, Mucinous; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Estrogens; Female; Galantamine; Humans; Mammography; Mastectomy; Neoplasms, Hormone-Dependent; Nitriles; Paraneoplastic Syndromes; Pravastatin; Progesterone; Radiotherapy, Adjuvant; Raynaud Disease; Seasons; Triazoles; Verapamil

2010
Statins and cancer development.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2005, Volume: 14, Issue:8

    Topics: Animals; Breast Neoplasms; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Pravastatin

2005

Other Studies

6 other study(ies) available for pravastatin and Breast Cancer

ArticleYear
Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines.
    Journal of cancer research and clinical oncology, 1995, Volume: 121, Issue:6

    Topics: Blotting, Southern; Breast Neoplasms; Cell Division; Cholesterol, LDL; Dose-Response Relationship, Drug; Gene Expression; Humans; Hydroxymethylglutaryl CoA Reductases; Immunohistochemistry; Polymerase Chain Reaction; Pravastatin; RNA, Messenger; RNA, Neoplasm; Stomach Neoplasms; Tumor Cells, Cultured

1995
The effect of pravastatin on coronary events after myocardial infarction.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Breast Neoplasms; Coronary Disease; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Pravastatin

1997
Update in women's health.
    Annals of internal medicine, 2000, Sep-05, Volume: 133, Issue:5

    Topics: Anticholesteremic Agents; Breast Neoplasms; Clinical Trials as Topic; Coronary Artery Disease; Female; Humans; Lovastatin; Pravastatin; Women's Health

2000
Statin induced myopathy does not show up in MIBI scintigraphy.
    Nuclear medicine communications, 2001, Volume: 22, Issue:5

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi

2001
Statin use, hyperlipidaemia, and the risk of breast cancer.
    British journal of cancer, 2002, May-06, Volume: 86, Issue:9

    Topics: Aged; Anticholesteremic Agents; Breast Neoplasms; Case-Control Studies; Drug Administration Schedule; Female; Humans; Hyperlipidemias; Middle Aged; Pravastatin; Risk Factors

2002
Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project.
    Circulation, 2002, May-21, Volume: 105, Issue:20

    Topics: Aged; Anticholesteremic Agents; Breast Neoplasms; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cohort Studies; Comorbidity; Demography; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Liver Diseases; Male; Middle Aged; Multivariate Analysis; Muscular Diseases; Pravastatin; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Renal Insufficiency; Risk; Risk Assessment; Time

2002